Antibodies to hepatitis C virus asialoglycoproteins

US7105303B2 · kind B2 · utility

Assignee

• Novartis Vaccines and Diagnostics, Inc. · US

Inventors

• Robert O. Ralston · Danville, US
• Frank Marcus · Lake in the Hills, US
• Kent B. Thudium · Oakland, US
• Barbara A. Gervase · Vallejo, US
• John A. Hall · Abdulrahman Khaleefah Street, US
• Kim M. Berger · Lafayette, US
• Qui-Lim Choo · Corona, US
• Michael Houghton · Berkeley, US
• George Kuo · San Francisco, US

Key dates

• Filing date: Aug 13, 2001
• Grant date: Sep 12, 2006
• Expiry date: Aug 13, 2021

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S977/918
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.